NCT06369831

HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2024-09-12Est. Completion: 2026-12-31

Enrollment target: 60 participants

Locations

Medizinische Universität Innsbruck, Innsbruck, Tyrol, Austria
AZ Delta CHIREC, Brussels, Brussels Capital, Belgium
Cliniques Universitaires Saint-Luc, Brussels, Brussels Capital, Belgium
Free University Brussels (VUB), Brussels, Brussels Capital, Belgium
Institut Jules Bordet, Brussels, Brussels Capital, Belgium
OLV Aalst, Aalst, East-Flanders, Belgium
University Hospital Gasthuisberg, Leuven, Belgium

Contact

Karine Clauwaertkarine.clauwaert@abscint.com +32476536594

Other microbiome trials you might be interested in

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Phase 3Recruiting

Non-small Cell Lung CancerNSCLC

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed …

Little Rock, United StatesEst. completion Jan 12, 2029

View Trial →

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider InterventionsRecruiting

Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.